18442-22-3

Basic information

• Product Name: 7-Bromo-4-chromanone
• Synonyms: 7-Bromo-4-chromanone;7-Bromo Chromonone;7-bromo-2,3-dihydrochromen-4-one;7-Bromo-2,3-dihydro-4H-1-benzopyran-4-one;7-broMo-3,4-dihydro-2H-1-benzopyran-4-one;7-BroMo-4-chroManone 97%;7-Bromochroman-4-one C9H7BrO2;7-bromo-2,3-dihydrobenzopyran-4-one
• CAS NO: 18442-22-3
• Molecular Formula: C₉H₇BrO₂
• Molecular Weight: 227.05468
• EINECS: 1308068-626-2
• Product Categories: 18442-22-3
• Mol File: 18442-22-3.mol

Chemical Properties

• Boiling Point: 336.585 °C at 760 mmHg
• Flash Point: 157.361 °C
• Appearance: /
• Density: 1.622 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.599
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 7-Bromo-4-chromanone(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Bromo-4-chromanone(18442-22-3)
• EPA Substance Registry System: 7-Bromo-4-chromanone(18442-22-3)

Safety Data

• Hazardous Substances Data: 18442-22-3(Hazardous Substances Data)

Usage

Uses

Used as a?intermediate for??R & D.

Synthesis

7-Bromochroman-4-one was synthesized by hydrogenation addition of 7-Bromo-benzopyrone catalyzed by Wilkinson's catalyst Rhodium( Ⅰ) tris( triphenylphosphine) chloride[Rh( PPh3)3Cl]. The structure was confirmed by1 H NMR and MS. The optimum reaction conditions for synthesizing 7-Bromochroman-4-one were as follows: 5 0. 329 mol,ethanol as the solvent,c( 5) =0. 4 mol·L- 1,4% mol Rh( PPh3)3Cl as the catalyst,under 0. 3 MPa of hydrogen pressure,at 70℃ for 20 h,the yield was 79. 8%.

InChI:InChI=1/C9H7BrO2/c10-6-1-2-7-8(11)3-4-12-9(7)5-6/h1-2,5H,3-4H2

Upstream product

• 591-20-8 3-Bromophenol 
• 1016736-70-1 3-(3-bromophenoxy)propanenitrile 
• 288067-35-6 4-bromo-2-hydroxy-benzonitrile 
• 876149-55-2 C₁₁H₁₂BrNO₂ 
• 945724-02-7 (E)-1-(4-bromo-2-hydroxyphenyl)-3-(dimethylamino)prop-2-en-1-one 
• 30186-18-6 4'-bromo-2'-hydroxyacetophenone 
• 1493-13-6 trifluorormethanesulfonic acid 
• 18386-03-3 3-(3-bromophenoxy)propionic acid 
• 491-37-2 2,3-dihydro-4H-1-benzopyran-4-one 
• 168759-60-2 7-bromo-4H-benzopyran-4-one 
• 890840-78-5 C₉H₆BrClO 

Downstream Products

• 1180671-97-9 7-bromo-3-amino-chroman-4-one hydrochloride 
• 1180671-95-7 (E,Z)-7-bromochroman-4-one O-tosyl oxime 
• 1616267-48-1 7-(3-fluorophenyl)-3,4-dihydro-2H-chromen-4-one 

Relevant articles and documents

HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF

The present invention relates to a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the treatment of various HAT-related diseases or conditions.

Acid activated montmorillonite K-10 mediated intramolecular acylation: Simple and convenient synthesis of 4-chromanones

3-Aryloxyproionic acids undergo intramolecular cyclization in the presence of AA.Mont.K-10 in toluene under reflux for 30–45 min in good to excellent yields. Phenyl ring bearing various substituents at the ortho, meta, para positions undergo this cyclization reaction. This method involves simple work up and amenable for large scale preparations. The heterogeneous acid treated catalyst can be regenerated and used for up to three cycles with minimum loss of activity.

PPAR (peroxisome proliferator-activated receptor) agonist and application thereof to treatment of senile dementia and other diseases

The invention relates to a compound, namely a gamma-subtype peroxisome proliferator-activated receptor (PPAR) agonist. In addition, the invention discloses a medicinal component and a preparation containing the compound and application of such the gamma-subtype PPAR agonist.

CHROMANE-SUBSTITUED TETRACYCLIC COMPOUNDS AND USES THEREOF FOR TREATMENT OF VIRAL DISEASES

Disclosed are novel chromane-substituted tetracyclic compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, A', R2 R3, R4 and R5 are as defined in the description. Also disclosed are compositions comprising a chromane-substituted tetracyclic compound, and methods of using the chromane-substituted tetracyclic compounds for treating or preventing HCV infection in a patient.

ARYL SULFONAMIDES AS BLT1 ANTAGONISTS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene B4 receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leu

ARYL SULFONAMIDES AS BLT1 ANTAGONISTS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene B4 receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leu

Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants

The discovery of potent and pan-genotypic HCV NS5A inhibitors faces many challenges including the significant diversity among genotypes, substantial potency shift conferred on some key resistance-associated variants, inconsistent SARs between different genotypes and mutants, and the lacking of models of inhibitor/protein complexes for rational inhibitor design. As part of ongoing efforts on HCV NS5A inhibition at Merck, we now describe the discovery of a novel series of chromane containing NS5A inhibitors. SAR studies around the "Z" group of the tetracyclic indole scaffold explored fused bicyclic rings as alternates to the phenyl group of elbasvir (1, MK-8742) and identified novel chromane and 2,3-dihydrobenzofuran derivatives as "Z" group replacements offered good potency across all genotypes. This effort, incorporating the C-1 fluoro substitution at the tetracyclic indole core, led to the discovery of a new series of NS5A inhibitors, such as compounds 14 and 25-28, with significantly improved potency against resistance-associated variants, such as GT2b, GT1a Y93H, and GT1a L31V. Compound 14 also showed reasonable PK exposures in preclinical species (rat and dog).

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

ANTIVIRAL COMPOUNDS

The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

NOVEL ARYL UREA DERIVATIVE

There is a need for FAAH inhibitors capable of oral administration and having excellent efficacy, particularly agents for the prevention and treatment of pain. Disclosed are novel arylurea compounds represented by formula (I), salts or solvates thereof, and pharmaceutical compositions comprising the same as an active ingredient. The pharmaceutical composition is used primarily for FAAH inhibitors, or agents for prevention and treatment of pain.